StomTop

Company Overview

Snapshot

Founded in December 2019 by Nurit Eyal and Dror Eyal, StomTop operates with 1–10 employees. The company has raised $1.24M across two funding rounds. In September 2021, StomTop secured equity crowdfunding from PipelBiz.

Business overview

StomTop develops medical solutions for ostomates, focusing on devices that provide internal intestinal sealing rather than external adhesion to the abdomen skin. These devices are designed to offer a leak-proof experience and prevent peristomal skin complications, regardless of the stoma or skin conditions. Operating within the Health Tech & Life Sciences sector, specifically in Medical Devices, StomTop serves the healthcare industry with its innovative treatments and technologies.

Strategic signal

In May 2021, StomTop was featured in Geektime for its Israeli development aimed at improving the lives of millions suffering from bowel diseases. This highlights the company's potential to address significant unmet needs in the ostomy care market and signals strong market validation for its innovative approach to medical device technology.

Company Intelligence Q&A

What is StomTop's primary focus?

StomTop focuses on developing medical solutions for individuals with a stoma, known as ostomates, aiming to improve their quality of life through advanced device technology.

When was StomTop founded and by whom?

StomTop was founded in December 2019 by co-founders Nurit Eyal, who serves as CEO, and Dror Eyal, the CTO.

What is the core technology behind StomTop's products?

StomTop's devices are based on internal intestinal sealing, designed to offer a leak-proof experience and eliminate peristomal skin complications, distinguishing them from traditional adhesion-based solutions.

What was a significant funding event for StomTop?

In September 2021, StomTop secured equity crowdfunding from PipelBiz, contributing to its total capital raised of $1.24M across two funding rounds.

What is the current product stage for StomTop?

StomTop's products, such as SILTOP, are currently in the clinical trial stage, indicating ongoing development and testing towards market readiness.